Get started
Author

M. Sugihara

1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the exploratory cohorts in the phase II, multicenter, open-label DESTINY-Gastric01 study
2020 · K. Yamaguchi, Y-J. Bang, et al. · Annals of Oncology · 44
PDF
An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients
2015 · W Ichikawa, K Uehara, et al. · British Journal of Cancer · 31
PDF
Abstract P6-17-02: Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-low expressing breast cancer: Updated results of a large phase 1 study
2019 · S Modi, J Tsurutani, et al. · Cancer Research · 27
OA02.07 Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or –Mutated Advanced Non-Small-Cell Lung Cancer
2018 · J. Tsurutani, H. Park, et al. · Journal of Thoracic Oncology · 27
PDF
O-14 Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gastroesophageal junction adenocarcinoma
2021 · K. Shitara, Y. Bang, et al. · Annals of Oncology · 14
Abstract P6-17-10: Dose justification for DS-8201a, a HER2-targeted antibody-drug conjugate, for HER2-positive breast cancer: Observed clinical data and exposure-response analyses
2019 · K Tamura, S Modi, et al. · Cancer Research · 9
Updated results of phase I study of trastuzumab deruxtecan (DS-8201a) in HER2-expressing advanced colorectal cancer
2018 · T. Yoshino, H. Iwata, et al. · Annals of Oncology · 7
O-11 Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, phase 2, multicenter, open-label study (DESTINY-Gastric01)
2020 · K. Yamaguchi, Y. Bang, et al. · Annals of Oncology · 5
286P Artificial intelligence analysis of advanced breast cancer patients from a phase I trial of trastuzumab deruxtecan (T-DxD): HER2 and histopathology features as predictors of clinical benefit
2020 · S. Modi, B. Glass, et al. · Annals of Oncology · 4
Multicenter phase II study of triple combination with S-1 and cisplatin (CDDP) plus paclitaxel (TXL) in patients with advanced gastric cancer
2008 · H. Iwase, T. Tsuzuki, et al. · Journal of Clinical Oncology · 2
A nomogram for predicting overall survival (OS) in Japanese patients (pts) with advanced colorectal cancer (aCRC) treated with irinotecan (IRI)-based regimens
2016 · W. Ichikawa, K. Uehara, et al. · Annals of Oncology · 1
2100 Impact of UGT1A1 genotype and irinotecan exposure on outcomes in Japanese patients with advanced colorectal cancer treated by irinotecan-based regimens
2015 · W. Ichikawa, K. Uehara, et al. · European Journal of Cancer · 1
Extended safety and efficacy data on triple combination therapy using S-1, cisplatin, and paclitaxel in patients with advanced gastric cancer in a multicenter phase II study.
2010 · H. Iwase, K. Ina, et al. · Journal of Clinical Oncology · 1
A randomized, phase II, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing gastric cancer
2018 · K. Shitara, Y.-J. Bang, et al. · Annals of Oncology
Superficial depressed colorectal adenocarcinomas and adenomas: Clinicopathological study
1998 · M. Hayakawa, K. Kusugami, et al. · Gastroenterology
PDF
Works count: 15
Citation count: 173
H-index: 7
I10-index: 5
Year
Topic
Type